CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 78 enrolled
Drug / intervention
Buprenorphine Transdermal Patchdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02519387
NCT02519387Phase 4Completed
CompareCT.gov

Multicentre Study for Evaluation of the Efficacy and Safety of Buprenorphine Transdermal Patch (SOVENOR®) 5mg and 10mg in Patients With Non-malignant Pain of Moderate Intensity Due to Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain and Joint/Muscle Pain, When an Opioid is Necessary for Obtaining Adequate Analgesia

Mundipharma Pharmaceuticals Sdn. Bhd.·interventional·Posted Aug 10, 2015·Updated Jul 20, 2016

In Brief

A Phase 4 clinical trial evaluating Buprenorphine Transdermal Patch for Osteoarthritis and 4 related conditions. Completed, enrolled 78 participants across 3 sites.

Detailed Summary

This is a phase IV, open-label and single-arm study of patients with non-malignant pain due to osteoarthritis, rheumatoid arthritis, low back pain and joint/muscle pain, who were not responding to non-opioid analgesics. The primary objective was to assess the efficacy of buprenorphine transdermal patch for pain control among these patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Rheumatoid Arthritis, Lower Back Pain, Joint Pain, Muscle Pain
CountriesMalaysia
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 10, 2015
Enrollment StartJul 1, 2013
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.9 years ago

Interventions

Buprenorphine Transdermal Patchdrug